News for Healthier Living

GEMMABio Announces Clinical Trial Authorization for New SMA1 Gene Therapy

Gemma Biotherapeutics ("GEMMABio"), a leading global genetic medicines company, announced that its novel gene therapy for spinal muscular atrophy type 1 (SMA1) is cleared for clinical trial by ANVISA, the health regulatory agency in Brazil.

November 24, 2025


November 25 2025

November 24 2025

November 23 2025

November 22 2025

November 21 2025

November 20 2025

November 19 2025

November 18 2025

November 17 2025

November 16 2025

November 15 2025

November 14 2025

November 13 2025

November 12 2025

November 11 2025